Maria Banzi

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study

Thierry André, Armand de Gramont, Déwi Vernerey et al. · Journal of Clinical Oncology · 2015 · 675 citations

Medicine, Molecular Genetics, Oncology +17

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Tiziana Pressiani, C. Boni, Lorenza Rimassa et al. · Annals of Oncology · 2012 · 152 citations · Full text

Medicine, Oncology, Hepatic Pharmacokinetics +12

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Eric Van Cutsem, Erika Martinelli, Stefano Cascinu et al. · The Oncologist · 2018 · 143 citations · Full text

Medicine, Oncology, Pharmacology +15

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial

Alberto Sobrero, Sara Lonardi, Gerardo Rosati et al. · Journal of Clinical Oncology · 2018 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17